Holen Sie sich die Stockscreener-App
220.83
1.64%
-3.68
Handel nachbörslich:
220.90
0.07
+0.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$224.51
Offen:
$221.15
24-Stunden-Volumen:
464.80K
Relative Volume:
0.43
Marktkapitalisierung:
$32.63B
Einnahmen:
$9.60B
Nettoeinkommen (Verlust:
$1.37B
KGV:
23.70
EPS:
9.3182
Netto-Cashflow:
$2.32B
1W Leistung:
+1.07%
1M Leistung:
+5.94%
6M Leistung:
+16.26%
1J Leistung:
+57.80%
1-Tages-Spanne:
$219.82
$223.82
1-Wochen-Bereich:
$213.58
$225.80
52-Wochen-Spanne:
$135.39
$225.80
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
220.83 | 31.67B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,149.36 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.23 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.46 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.33 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.99 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Hochstufung | UBS | Neutral → Buy |
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Inc. stock holds near 12 month high on steady Q1 2026 growth - AD HOC NEWS
BIIB Stock Price Prediction 2026-2027 | Biogen Forecast - 24/7 Wall St.
Biogen Inc. (BIIB) Peer Comparison – Compare with Others - Value Research
Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi - marketscreener.com
Biogen (BIIB), Why Is Its Latest Update Drawing Fresh Attention? - simplywall.st
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Biogen
Stoke Therapeutics and Biogen Present Long-Term Clinical - GlobeNewswire
Biogen (BIIB) awards 7,405 stock units to its top lawyer - Stock Titan
Biogen Is Repositioning Its Portfolio To Partly Offset Ongoing Revenue Declines - Morningstar
Eisai, Biogen Win China Approval for Leqembi Self-Injection - jp.ibtimes.com
Price cut becomes the price of coverage for Alzheimer's drug lecanemab - Benefits and Pensions Monitor
Eisai and Biogen Announce China Approval of LEQEMBI SC-AI for Initiation Treatment of Early Alzheimer’s Disease - Quiver Quantitative
How Biogen’s (BIIB) At-Home LEQEMBI Injections Could Reframe the Alzheimer’s Treatment Investment Story - simplywall.st
Biogen Inc (BIIB) Shares Surge 3.1% -- What GF Score of 73 Tells Investors - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - marketwatch.com
Biogen gains as pipeline updates and fresh Street target hikes buoy sentiment - Quiver Quantitative
Biogen stock hits 52-week high at 222.86 USD By Investing.com - Investing.com Canada
Biogen stock hits 52-week high at 222.86 USD - Investing.com
A potential seizure treatment will be presented Sept. 9 by Stoke Therapeutics - Stock Titan
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome - Investing.com
Stoke Therapeutics and Biogen Announce Presentations of - GlobeNewswire
Eisai and Biogen Announce Canada’s Drug Agency Final Recommendation Supporting Public Reimbursement of LEQEMBI for Eligible Early Alzheimer’s Disease Patients - Quiver Quantitative
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease - Biogen
Final CDA-AMC Recommendation Brings Canadians with Early-Stage Alzheimer's Disease One Step Closer to Accessing LEQEMBI® (lecanemab) - PR Newswire Canada
Price to book forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Biogen Inc. (BIIB) Stock Report: Analyst Ratings Signal Potential Upside Of Over 8% - DirectorsTalk Interviews
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report? - Yahoo Finance
Will Biogen (BIIB) Make Early Alzheimer’s Treatment Easier At Home? - simplywall.st
Eisai and Biogen Launch LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer’s Disease in the U.S. - Quiver Quantitative
Biogen Inc. (BIIB) Stock Analysis: Evaluating a Potential 8.67% Upside in the Healthcare Sector - DirectorsTalk Interviews
Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial - TipRanks
Biogen Inc. (NASDAQ:BIIB) Healthcare Momentum Draws Fresh Market Attention - Kalkine Media
What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders - Yahoo Finance
OVERSEA CHINESE BANKING Corp Ltd Purchases Shares of 18,867 Biogen Inc. $BIIB - MarketBeat
Wealthfront Advisers LLC Acquires Shares of 16,529 Biogen Inc. $BIIB - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Acquires Shares of 13,000 Biogen Inc. $BIIB - MarketBeat
66,365 Shares in Biogen Inc. $BIIB Bought by Danske Bank A S - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Biogen (BIIB) And The Alzheimer’s Narrative As Valuation Stays In Focus - simplywall.st
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month? - TradingView
Impax Global Women's Leadership Fund's Biogen Inc(BIIB) Holding History - GuruFocus
Is Wall Street Bullish or Bearish on Biogen Stock? - Barchart.com
Meeder Advisory Services Inc. Acquires Shares of 4,608 Biogen Inc. $BIIB - MarketBeat
Edmond DE Rothschild Holding S.A. Makes New Investment in Biogen Inc. $BIIB - MarketBeat
BIIB Stock Price Prediction 2025-2026 | Biogen Inc Forecast - 24/7 Wall St.
Biogen Inc (BIIB) Stock Up 4.2% but GF Value Says Overvalued -- GF Score: 73/100 - GuruFocus
Biogen (NASDAQ:BIIB) Sets New 1-Year HighTime to Buy? - MarketBeat
Biogen (BIIB) Stock Surges to 52-Week Peak After BlackRock’s $3.4B Investment - Blockonomi
Biogen stock hits 52-week high at 219.94 USD - Investing.com
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biogen Inc-Aktie (BIIB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Minor Lloyd | Director |
Aug 04 '26 |
Sale |
200.96 |
593 |
119,169 |
2,689 |
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):